• Profile

Declining disease burden of hepatocellular carcinoma in the US, 1992-2017: A population-based analysis

Hepatology Jan 27, 2022

Since 2013, the overall hepatocellular carcinoma (HCC)-specific mortality has decreased significantly, along with reduced incidence and continuously improved survival, in the US population. Possible contributors to the downward trends of the disease burden of HCC in the US include changing etiologies, advances in screening and diagnosis, and improved treatment modality and allocation.

  • Researchers utilized data from the Surveillance, Epidemiology, and End Results databases, to analyze HCC incidence, incidence-based mortality (IBM), and 1-year survival (1-YS) rates from 1992 through 2017 in the US.

  • During 1992-2011, an increase in the incidence rates of HCC occurred, and incidence rates sharply declined thereafter by -2.3% annually.

  • In the US population, IBM peaked in 2013 (age-standardized mortality rate: 6.98 per 100,000 person-years).

  • Significant reduction in IBM began in 2013 by -3.2%/year (/y) after a continuous increase of 3.5% annually during 1993-2013.

  • Improvement in the 1-YS of HCC, from 21.4% to 56.6%, was observed during the study period.

  • However, HCC incidence and mortality risk were highest in patients aged 60-69 and born between 1952-1957.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen